JP2020507582A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507582A5
JP2020507582A5 JP2019543377A JP2019543377A JP2020507582A5 JP 2020507582 A5 JP2020507582 A5 JP 2020507582A5 JP 2019543377 A JP2019543377 A JP 2019543377A JP 2019543377 A JP2019543377 A JP 2019543377A JP 2020507582 A5 JP2020507582 A5 JP 2020507582A5
Authority
JP
Japan
Prior art keywords
alkyl
haloalkyl
aryl
cycloalkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019543377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507582A (ja
JP7097373B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/017755 external-priority patent/WO2018148626A1/en
Publication of JP2020507582A publication Critical patent/JP2020507582A/ja
Publication of JP2020507582A5 publication Critical patent/JP2020507582A5/ja
Application granted granted Critical
Publication of JP7097373B2 publication Critical patent/JP7097373B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019543377A 2017-02-13 2018-02-12 キナーゼ阻害剤としてのアミノトリアゾロピリジン Active JP7097373B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13
US62/458,144 2017-02-13
PCT/US2018/017755 WO2018148626A1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2020507582A JP2020507582A (ja) 2020-03-12
JP2020507582A5 true JP2020507582A5 (enExample) 2021-03-18
JP7097373B2 JP7097373B2 (ja) 2022-07-07

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019543377A Active JP7097373B2 (ja) 2017-02-13 2018-02-12 キナーゼ阻害剤としてのアミノトリアゾロピリジン

Country Status (25)

Country Link
US (3) US10913738B2 (enExample)
EP (1) EP3580220B1 (enExample)
JP (1) JP7097373B2 (enExample)
KR (1) KR102549952B1 (enExample)
CN (1) CN110520423B (enExample)
AU (1) AU2018217488B2 (enExample)
BR (1) BR112019016635A2 (enExample)
CA (1) CA3053484A1 (enExample)
CY (1) CY1124978T1 (enExample)
DK (1) DK3580220T3 (enExample)
EA (1) EA039808B1 (enExample)
ES (1) ES2902676T3 (enExample)
HR (1) HRP20212000T1 (enExample)
HU (1) HUE057801T2 (enExample)
IL (1) IL268614B (enExample)
LT (1) LT3580220T (enExample)
MA (1) MA47460A (enExample)
MX (1) MX378515B (enExample)
PL (1) PL3580220T3 (enExample)
PT (1) PT3580220T (enExample)
RS (1) RS62801B1 (enExample)
SG (1) SG11201907335UA (enExample)
SI (1) SI3580220T1 (enExample)
SM (1) SMT202200001T1 (enExample)
WO (1) WO2018148626A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3580220B1 (en) * 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
KR102662197B1 (ko) * 2017-10-30 2024-04-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 아미노이미다조피리다진
JP7307734B2 (ja) 2018-01-26 2023-07-12 ブリストル-マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのアミノピロロトリアジン
AU2019301628C1 (en) 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
WO2020014243A1 (en) * 2018-07-09 2020-01-16 Lieber Institute, Inc. PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
CA3112519A1 (en) 2018-09-13 2020-03-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
AU2019337612A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)
CN113166116B (zh) * 2019-01-25 2022-12-27 北京赛特明强医药科技有限公司 酰胺基桥连杂环类化合物、及其组合物与应用
US20220177462A1 (en) * 2019-03-22 2022-06-09 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof
JP7600228B2 (ja) 2019-10-03 2024-12-16 ブリストル-マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのインダゾールカルボキサミド
JP7441477B2 (ja) * 2020-02-13 2024-03-01 ▲勁▼方医▲薬▼科技(上海)有限公司 ジヒドロナフチリドン系化合物、その調製方法及び医薬への使用
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
IL308349A (en) 2021-08-10 2024-01-01 Abbvie Inc NICOTINAMIDE RIPK1 INHIBITORS
TW202345852A (zh) 2022-03-16 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠雜環類化合物、其製備方法及其在醫藥上的應用
CN114989079B (zh) * 2022-06-21 2023-06-23 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025072395A1 (en) * 2023-09-27 2025-04-03 Bristol-Myers Squibb Company Triazolopyridinyl compounds as kinase inhibitors
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288502A1 (en) * 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
MX2008012482A (es) * 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
WO2009068482A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
US8598163B2 (en) 2009-02-04 2013-12-03 Vitae Pharmaceuticals, Inc. Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
TN2015000542A1 (en) 2013-06-10 2017-04-06 Bayer Pharma AG Novel compounds for the treatment of cancer
CA2958645A1 (en) * 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
CN108349970B (zh) * 2015-11-05 2021-03-05 住友化学株式会社 稠合杂环化合物
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
JP7190906B2 (ja) 2017-01-24 2022-12-16 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
EP3580220B1 (en) * 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
KR102662197B1 (ko) 2017-10-30 2024-04-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 아미노이미다조피리다진
JP7307734B2 (ja) 2018-01-26 2023-07-12 ブリストル-マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのアミノピロロトリアジン
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Similar Documents

Publication Publication Date Title
JP2020507582A5 (enExample)
AU2013213260B2 (en) Imidazopyrrolidinone compounds
JOP20220101A1 (ar) مثبطات صغيرة الجزئ لطافر G12C لبروتين ساركوما جرذان Kirsten (KRAS)
JP2019519586A5 (enExample)
JP2013532652A5 (enExample)
JP2018502877A5 (enExample)
JP2013507425A5 (enExample)
JP2020521767A5 (enExample)
JP2016514719A5 (enExample)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
JP2019034943A5 (enExample)
JP2016520618A5 (enExample)
JP2013502431A5 (enExample)
JP2004518651A5 (enExample)
JP2019534260A5 (enExample)
JP2014500295A5 (enExample)
JP2004525149A5 (enExample)
JP2007519694A5 (enExample)
JP2008523041A5 (enExample)
RU2013123275A (ru) Пиперидин-4-илазетидиндиамиды как ингибиторы моноацилглицеринлипазы
JP2009538897A5 (enExample)
JP2005533748A5 (enExample)
JP2016512511A5 (enExample)
JP2007516205A5 (enExample)
JP2011526917A5 (enExample)